Becton Dickinson (BDX) stock fell by 1.81% ahead of its upcoming Q3 2025 earnings report, as analysts recently downgraded the stock from "buy" to "neutral" and reduced target prices, indicating concerns about its future performance.

Becton Dickinson (BDX) stock fell by 1

Becton, Dickinson and Company (BDX) stock decreased by 0.46% amid a mixed consensus rating from analysts, with several firms downgrading their ratings and price targets, contributing to negative market sentiment.

Becton, Dickinson and Company (BDX) stock decreased by 0

Becton, Dickinson and Company (BDX) experienced a decline of 1.13% in stock price due to lowered Q3 2025 earnings estimates by analysts at William Blair and downgrades from several other equity research firms, resulting in reduced investor confidence.

Becton, Dickinson and Company (BDX) experienced a decline of 1

Becton, Dickinson and Company (BDX) stock rose by 1.48% despite analysts decreasing their Q4 2025 earnings estimates, likely due to ongoing investor interest and support as institutional holdings remain high, along with a solid dividend payout.

Becton, Dickinson and Company (BDX) stock rose by 1

Becton Dickinson (BDX) stock increased by 0.64% due to ongoing investigations concerning potential fiduciary duty breaches related to mergers and acquisitions in the healthcare sector, including BD's merger with Waters Corporation, which may influence shareholder confidence and market perception.

Becton Dickinson (BDX) stock increased by 0

Becton Dickinson (BDX) stock was up by 0.64% last night, likely due to a general market rally as recession fears diminished, inspiring increased risk-taking among investors.

Becton Dickinson (BDX) stock was up by 0

Becton Dickinson (BDX) stock rose by 0.64% due to the announcement of its plan to spin off its biosciences and diagnostic business and merge it with Waters, using at least $2 billion of the proceeds for stock buybacks.

Becton Dickinson (BDX) stock rose by 0

Becton, Dickinson and Company (BDX) stock declined by 0.63% following several analysts' downgrades and lowered price targets, along with disappointing revenue figures that fell short of expectations in its recent earnings report.

Becton, Dickinson and Company (BDX) stock declined by 0

Becton, Dickinson and Company (BDX) stock rose 0.81% due to increased institutional investor interest, including significant stake increases by firms like Sequoia Financial Advisors and T. Rowe Price, coupled with a recent earnings beat despite mixed analyst ratings and stock price target adjustments.

Becton, Dickinson and Company (BDX) stock rose 0

Becton, Dickinson and Company (BDX) stock rose by 0.81% last night, following increased institutional investment and a positive earnings report that exceeded analysts' expectations. The uptick is attributed to Perpetual Ltd and other institutional investors expanding their stakes in the company, signaling confidence in BDX's future performance.

Becton, Dickinson and Company (BDX) stock rose by 0

Becton, Dickinson and Company's (BDX) stock rose by 0.52% recently despite a downgrade in Q3 2025 earnings estimates by Zacks Research, potentially driven by the company's strong performance in previous quarters and ongoing interest from institutional investors.

Becton, Dickinson and Company's (BDX) stock rose by 0

Becton, Dickinson and Company (BDX) saw its stock increase by 0.52% following a mixed bag of institutional investment activities and a recently reported quarterly earnings performance that exceeded analyst expectations. The stock's rise can be attributed to positive momentum from its earnings report and ongoing interest from institutional investors, despite some fund managers reducing their positions.

Becton, Dickinson and Company (BDX) saw its stock increase by 0

Becton Dickinson (BDX) stock declined by 0.54% due to a series of institutional sell-offs, including a notable reduction in holdings by Flagship Harbor Advisors LLC, alongside several analyst downgrades and lowered price targets which may have impacted investor sentiment.

Becton Dickinson (BDX) stock declined by 0

Becton, Dickinson and Company (BDX) stock decreased by 0.39% largely due to institutional investors reducing their holdings, several equity analysts downgrading their ratings, and mixed earnings results that did not meet revenue estimates, despite beating earnings per share expectations.

Becton, Dickinson and Company (BDX) stock has declined over 20% this year, recently dropping by 0.39%, primarily due to weakened demand in diagnostics and biosciences, tariffs on Chinese imports, and concerns following the company's guidance cuts, alongside pressures from activist investor Starboard Value for operational changes to enhance shareholder value.

Becton, Dickinson and Company (BDX) stock has declined over 20% this year, recently dropping by 0

Becton, Dickinson and Company (BDX) stock rose by 1.09% likely due to strong quarterly earnings that exceeded analysts' expectations, as well as a solid dividend announcement, despite mixed ratings from analysts and significant reductions in holdings by some hedge funds.

Becton, Dickinson and Company (BDX) saw its stock decline by 0.79% due to multiple downgrades from research firms, analysts lowering their price targets, and recent insider selling, which contributed to negative investor sentiment.

Becton, Dickinson and Company (BDX) saw its stock decline by 0

Becton, Dickinson and Company (NYSE: BDX) saw a slight decline of 0.06% in its stock price due to a combination of institutional investors reducing their holdings, recent insider stock sales, and downgrades from multiple financial analysts affecting market sentiment.

Becton, Dickinson and Company (NYSE: BDX) saw a slight decline of 0

Becton Dickinson (BDX) stock declined by 0.06% largely due to institutional investor CVA Family Office LLC cutting its holdings by 65.6%, alongside a series of downgrades and reduced price targets from multiple equity analysts.

Becton Dickinson (BDX) stock fell by 1.29% amid a backdrop of lowered ratings and target prices from several analysts, signaling concerns over its financial performance despite a recent earnings beat.

Becton, Dickinson and Company (BDX) stock fell by 0.96% due to several factors including a reported revenue shortfall in its latest earnings, downgrades in analysts' ratings, and insider stock sales.

Becton, Dickinson and Company (BDX) stock fell by 0

Becton, Dickinson and Company (BDX) shares fell by 0.96%, primarily influenced by recent downgrades from several analysts, including reductions in price targets and ratings, along with insider sales decreasing executive ownership in the company.

Becton, Dickinson and Company (BDX) shares fell by 0

Becton, Dickinson and Company (BDX) stock rose by 1.09% following increased institutional investment, with Congress Asset Management Co. boosting its stake by 7.9%, alongside other positive shifts in institutional holdings, indicating growing investor confidence in the company's financial strength and recent earnings performance.

Becton, Dickinson and Company (BDX) stock rose by 1.09% following a series of analysts' ratings adjustments and a positive quarterly earnings report that exceeded estimates, despite concerns over lowered price targets from some analysts. The stock's increase can be attributed to its recent earnings performance and ongoing interest from institutional investors, despite mixed ratings from analysts.

Becton, Dickinson and Company (BDX) stock rose by 0.16% despite recent price target reductions by multiple analysts, as it reported better-than-expected quarterly earnings, beating consensus estimates and announcing a dividend payout, which likely contributed to increased investor confidence.

Becton Dickinson (BDX) stock declined by 0.48% after Citi analysts downgraded its rating from Buy to Neutral amidst concerns about the impact of recent tariff changes on future guidance and overall market volatility in the MedTech sector.

Becton, Dickinson and Company (BDX) stock declined by 0.21% following significant stake reduction by Gotham Asset Management LLC and recent downgrades by several brokerages, amidst a quarterly earnings report that, while beating EPS estimates, revealed lower-than-expected revenue.

Becton, Dickinson and Company (BDX) stock rose by 1.82% due to positive earnings results that exceeded analysts' expectations, along with a stock buyback plan indicating confidence from the company's leadership in the value of its shares.

Becton Dickinson (BDX) stock rose 4.86% primarily due to First Eagle Investment significantly increasing its stake in the company by 24.67%, reflecting strong institutional confidence in its long-term potential.

Becton Dickinson (BDX) stock rose 4

Becton, Dickinson and Company (BDX) saw a 1.2% increase in its stock price due to its listing among top medical stocks with high trading volumes, indicating investor interest amid broader trends in healthcare innovation and demand.

Becton, Dickinson and Company (BDX) saw a 1

Becton, Dickinson and Company (BDX) stock declined by -1.05% after Stifel Nicolaus lowered its price target significantly from $280 to $224 and following multiple downgrades from other analysts, impacting investor sentiment.

Becton, Dickinson and Company (BDX) stock declined by -1

Becton Dickinson (BDX) stock declined by 1.05% to $168.61 amid a higher trading volume than average, potentially influenced by market fluctuations affecting pharmaceutical stocks as well as factors such as clinical trial results, regulatory decisions, and economic conditions impacting the healthcare sector.

Becton Dickinson (BDX) stock declined by 1

Becton, Dickinson and Company's (BDX) stock declined by -1.05% following a series of downgrades from multiple brokerages, including Piper Sandler, which reduced its rating from overweight to neutral and lowered its price target significantly, indicating a cautious outlook on the stock.

Becton, Dickinson and Company's (BDX) stock declined by -1

Becton Dickinson (BDX) stock fell by 0.45% after the company lowered its fiscal year 2025 guidance and highlighted the impact of tariffs, despite reporting higher adjusted earnings per share that exceeded analysts' expectations.

Becton Dickinson (BDX) stock fell by 0

Becton Dickinson (BDX) stock dropped by 18.13% due to disappointing earnings reports and guidance, contributing to a significant decline in investor confidence amidst a generally positive market for tech stocks.

Becton Dickinson (BDX) stock dropped by 18

Becton, Dickinson and Company (BDX) stock rose by 0.31% due to strong earnings performance that exceeded analysts' expectations, as well as the announcement of a stock repurchase plan indicating the board's belief that the stock is undervalued.

Becton, Dickinson and Company (BDX) stock rose by 0.31% ahead of its anticipated Q2 2025 earnings release, where analysts expect positive results, including earnings of $3.28 per share and revenue of $5.35 billion, alongside recent actions like a stock buyback plan indicating confidence in the stock’s value.

The article discusses how T. Rowe Price is experiencing significant growth in actively managed exchange-traded funds (ETFs), with a specific mention of the T. Rowe Price Capital Appreciation Equity ETF and its holdings, including Becton Dickinson (BDX), which is up by 0.31% due to the attractiveness of professional management in volatile market conditions. 

Becton Dickinson (BDX) stock likely went up as part of a broader trend of investment in actively managed funds, which are perceived to perform better in uncertain market environments.

The article discusses how T

Becton, Dickinson and Company (BDX) stock decreased by 0.84% despite receiving a "Buy" rating from analysts and having an average target price of $275.71, which may be attributed to fluctuations in target price assessments by analysts, including Barclays lowering its price objective to $261.00.

Becton, Dickinson and Company (BDX) stock declined by 1.78% following a revision by Zacks Research, which lowered its FY2025 earnings per share estimate from $14.43 to $14.40, signaling concerns over future profitability.

Becton, Dickinson and Company (BDX) stock declined by 1

Becton Dickinson (BDX) stock fell by 4.89% amidst unusual options trading activity and recent insider sales, which may have raised concerns among investors despite the company reporting strong earnings and announcing a share repurchase plan.

Becton Dickinson (BDX) stock fell by 4

Becton, Dickinson and Company (BDX) shares rose by 4.24% likely due to a combination of strong earnings performance, an upgraded "buy" rating from StockNews.com, and ongoing investor interest despite a lowered price target from Barclays.

Becton, Dickinson and Company (BDX) shares rose by 4

Becton, Dickinson and Company (BDX) stock fell by 6.43% due to concerns over its long-term growth potential compared to other investment opportunities, particularly in AI stocks, as highlighted by Generation Investment Management's recent investor letter.

Becton, Dickinson and Company (BDX) stock fell by 6

Becton, Dickinson and Company (BDX) stock rose by 0.17% following an upgrade from a "hold" to a "buy" rating by StockNews.com, amid positive sentiments from other analysts who also raised price targets for the stock.

Becton, Dickinson and Company (BDX) stock rose 0.31% despite being downgraded to a "hold" rating, primarily due to positive earnings results exceeding analyst expectations and bullish price target increases from several analysts indicating strong market confidence.

Becton, Dickinson and Company (BDX) stock decreased by 0.45% despite receiving positive recommendations from analysts, likely due to insider selling and market movements despite a generally favorable outlook.

Becton, Dickinson and Company (BDX) stock rose by 1.43% despite a recent decline due to insider selling, as analysts upgraded their ratings and target prices, indicating confidence in the company's financial performance and future prospects.

Becton, Dickinson and Company (BDX) stock declined by 1.11% primarily due to the reduction of holdings by institutional investors, including a notable 3.8% cut by Victory Capital Management, alongside ongoing stock trading activities and market fluctuations.

Becton, Dickinson and Company (BDX) stock rose 1.86% following an upgrade from a "hold" to a "buy" rating by StockNews.com and positive price target adjustments from analysts, signaling improved investor confidence.

Becton, Dickinson and Company (BDX) stock rose 1

Becton Dickinson (BDX) stock rose by 0.54% due to findings from a significant study highlighting the critical role of Musashi-2 (Msi2) in lung adenocarcinoma, which suggests potential new therapeutic targets and advancements in understanding cancer biology that may positively influence investor sentiment.

Becton Dickinson (BDX) stock fell by 0.07% due to general market trends and possibly investor reactions to current geopolitical uncertainties affecting the healthcare industry.

The article does not directly address Becton Dickinson (BDX) stock's decline of -0.07%, but it provides a detailed notice about Suominen Corporation’s upcoming Annual General Meeting, discussing various agenda items including the election of board members and financial statements. The decline in BDX stock could be attributed to market fluctuations, investor sentiments, or company-specific news, but such details are not covered in this article.

The article does not directly address Becton Dickinson (BDX) stock's decline of -0

Becton, Dickinson and Company (BDX) stock declined by 1.51% following a downgrade from a "buy" rating to a "hold" rating by StockNews.com, despite other analysts maintaining positive outlooks on the stock.

BDX

Latest News & Analysis